Drugs / AFELETECAN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00040989 | — | renal cell carcinoma | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFELETECAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105857 ↗ |
| Known as | AFELETECAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105857 ↗ |
| Known as | Bay 38-3441 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105857 ↗ |
| Known as | BAY 56-3722 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040989 ↗ |
| Action | Inhibit | “BAY 56-3722 may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth.” NCT00040989 ↗ |
| Modality | Small molecule | — CHEMBL2105857 ↗ |
| Route | Intravenous | “BAY 56-3722 IV over 30 minutes” NCT00040989 ↗ |
| Target | TOP1 | “DNA topoisomerase I stabiliser” CHEMBL2105857 ↗ |